Bastei Lübbe AG / Key word(s): IPO 03.10.2013 08:11 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Cologne, 3 October 2013 - Bastei Lübbe AG, a leading German publishing and media group with renowned authors such as Dan Brown and Ken Follett completed its initial public offering (IPO) despite a challenging market environment, placing shares at an offering price of EUR 7.50 per share. 4,000,000 no par value ordinary bearer shares (shares) with a proportionate amount of the share capital of EUR 1.00 per share were placed. Of these, up to 3,300,000 million shares from a capital increase in Bastei Lübbe AG, which would raise the share capital of EUR10,000,000.00 to up to EUR13,300,000.00. Gross proceeds amounted to EUR30 million. Trading in Bastei Lübbe AG shares in the Prime Standard, the quality segment of the Regulated Market of the Frankfurt Stock Exchange characterized by the highest transparency requirements is planned for 8 October 2013. Bastei Lübbe AG plans to use the proceeds from the IPO in their business with focus on intensifying the development of own content as well as the content and rights acquisition of top-selling books and authors. Close Brothers Seydler Bank AG, based in Frankfurt am Main, acted as Sole Global Coordinator and Sole Bookrunner, and Conpair AG, based in Essen, acted as Financial Advisor on the IPO. About Bastei Lübbe AG Bastei Lübbe AG is a German publishing and media group long renowned for bringing popular fiction as well as non-fiction to the mass market. Its business activities include not only paperback and hardback books in print form but also audiobooks, e-books, and other digital publications. Its catalogue includes a wide range of fiction, non-fiction and entertainment products intended for a wide readership, including not only the various highly successful paperback fiction series for which Bastei Lübbe has long been famed but also puzzle books and magazines. The group's business activities additionally include the licensing of book rights and the creation, production and marketing of gift, decorative and merchandising articles. Bastei Lübbe also owns the following non-consolidated shareholdings in companies: 90% of Moravská Bastei MOBA, s.r.o. (Brno, Czech Republic), 100% of Bastei Media GmbH (Erfurt, Germany), 50% of PR�SENTA PROMOTION INTERNATIONAL GmbH (Solingen, Germany), and 100% of Bastei Lübbe Verwaltungs GmbH (Cologne, Germany). The company also has smaller shareholdings in various book and periodical distribution companies, none of which exceeds 5% of the respective company's registered capital. The business activities of Bastei Lübbe are broadly divided into segments: Books, Non-Books, and Popular Fiction and Puzzle Publications, which in turn include various product areas. The group publishes under 13 different labels, which span its full range of market segments and product areas. For the fiscal year 2012/2013, 80% of the group's revenues were derived from the Books segment, while 11% came from Non-Books and the remaining 9% from Popular Fiction and Puzzle Publications. At the end of its fiscal year 2012/2013, the number of staff employed by Bastei Lübbe was 265, compared to 210 at the close of the prior fiscal year. These figures do not include the 15 staff employed by its non-consolidated subsidiary Moravská Bastei MOBA, s.r.o. (Brno, Czech Republic), or at its other non-consolidated subsidiaries and affiliates (Bastei Media GmbH and PR�SENTA PROMOTION INTERNATIONAL GmbH). As of the date of the offering prospectus, the number of staff was 305, a further increase since the end of fiscal year 2012/2013. Barbara Fischer Bastei Lübbe AG Tel. +49 221 82002850 Fax +49 221 82001850 E-Mail: barbara.fischer@luebbe.de 03.10.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Bastei Lübbe AG Schanzenstra�e 6 - 20 51063 Köln Germany Phone: 02 21 / 82 00 - 0 Fax: 02 21 / 82 00 - 1900 E-mail: investorrelations@luebbe.de Internet: www.luebbe.de ISIN: DE000A1X3YY0, DE000A1K0169 WKN: A1X3YY, A1K016 Listed: Regulierter Markt in Frankfurt (Prime Standard) Notierung vorgesehen / intended to be listed End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Bastei Lübbe AG: Successful placement of
Top 10 Most Recent News Articles
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue ReadingTop 5 Most Recently Viewed Articles
Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns
Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....
Continue Reading
Photonics Market Poised for Massive Growth by 2030
Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...
Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units
Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...
Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200
Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...
Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update
The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...
Continue Reading